Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Science Translational Medicine|November 20, 2015
Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancerMelissa R Junttila, Weiguang Mao, Xi Wang, et al.Bioconjugate Chemistry|February 10, 2018
High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based LinkersRachana Ohri, Sunil Bhakta, Aimee Fourie-O'Donohue, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2010
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancerJagath R Junutula, Kelly M Flagella, Richard A Graham, et al.Molecular Cancer Therapeutics|December 29, 2017
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast CancerSunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.Molecular Pharmaceutics|April 9, 2015
An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancerSteven R Leong, Wei-Ching Liang, Yan Wu, et al.Mabs|December 31, 2020
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor responseJosefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, et al.Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.Nature Biotechnology|July 22, 2008
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexJagath R Junutula, Helga Raab, Suzanna Clark, et al.Molecular Cancer Therapeutics|February 23, 2017
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide LinkersThomas H Pillow, Melissa Schutten, Shang-Fan Yu, et al.Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.Pageof 6